Most of what gets written about TB-500 concerns tendons, rotator cuffs and hamstrings. So it is worth noting that the first randomised, placebo-controlled human trial to report an efficacy signal for injected thymosin beta-4 had nothing to do with soft-tissue injury at all. It was run in a cardiac catheterisation lab, in patients who had just had a heart attack — and its headline result was null.

If you have been searching "what is TB-500", "TB-500 research" or "is TB-500 legal in Australia", this trial is the most substantial human data point to land in years, and it says something quite different from what the injury-recovery marketing implies. Here is what it actually showed.

What is TB-500, and what was actually tested?

Thymosin beta-4 (Tβ4) is a 43-amino-acid, actin-sequestering protein found in most human cells. TB-500 — the thing sold in vials — is not that protein. It is a short synthetic fragment based on the actin-binding region (the LKKTETQ motif), usually N-acetylated. We have covered that distinction in detail, and it matters here, because the compound in the trial below was recombinant full-length human thymosin beta-4 (rhTB4), produced by Beijing Northland Biotech under the code NL005.

That product has a normal drug development history behind it: a first-in-human Phase I published in the Journal of Cellular and Molecular Medicine in 2021, with 54 healthy volunteers dosed intravenously across seven single-dose cohorts (0.05 to 25.0 µg/kg) and 30 more on a 10-day repeat-dose schedule. Adverse events were mild to moderate, with no dose-limiting toxicities or serious adverse events reported. Note the units: micrograms per kilogram, intravenously. A 70 kg adult at 1.0 µg/kg receives about 70 micrograms. The quantities described in injury-recovery protocols circulating online are milligram-scale and subcutaneous — a different molecule, a different route, and a dose scale no trial has tested for that purpose.

The 96-patient heart attack trial: what it found, and what it didn't

In December 2025, Cardiovascular Research published a two-part study of rhTB4 in ischaemia/reperfusion injury, combining mouse work with a human trial.

The animal half

In C57BL/6J mice, seven days of rhTB4 prevented cardiac dysfunction and fibrosis at 28 days after ischaemia/reperfusion surgery and reduced plasma NT-proBNP at both day 1 and day 28. In a separate permanent-ligation model, rhTB4 improved cardiac function and reduced infarct size at eight weeks. RNA sequencing of heart tissue pointed to modulation of the ErbB signalling pathway. This is consistent with a long preclinical literature on Tβ4 and cardiac repair — and, as always, it is rodent data.

The human half

The clinical component was a randomised, double-blind, placebo-controlled trial in 96 patients with ST-elevation myocardial infarction (STEMI) treated with primary PCI. Dosing was intravenous, in hospital, in the days immediately after the procedure. Cardiac MRI assessed infarct size and ventricular function.

The key result, stated plainly: across the full cohort of 96, the difference in infarcted area between rhTB4 and placebo was not statistically significant. A subgroup of patients who received their first dose within eight hours of PCI (n=43) did show significantly smaller infarcted areas than placebo at 90 days. The authors themselves conclude that further rigorous randomised studies are needed to establish whether early rhTB4 dosing after reperfusion matters.

That is a timing-based subgroup finding in a small, industry-sponsored trial, reported once. It is hypothesis-generating. It is not proof of benefit, and it has not been replicated. The design appears to correspond to a registered Phase IIb study of NL005 (NCT05984134), completed in May 2023, and a Phase IIc placebo-controlled study of the same agent is registered with a 2026 start.

One process note worth repeating for anyone verifying trials themselves: check the sponsor before you cite a registry entry. Beijing Northland Biotech is a real company with a published Phase I behind it. Not every peptide record on a trials registry has that lineage — some are demonstration or placeholder entries from organisations that do not exist.

Why this isn't evidence for injury recovery

Three gaps between this trial and the way TB-500 is discussed in gym and clinic circles:

  • Different molecule. Full-length recombinant Tβ4, not the acetylated seven-residue fragment.
  • Different indication and tissue. Acute reperfusion injury in myocardium, not tendon, ligament or muscle tear repair.
  • Different everything else. Intravenous administration, in hospital, at microgram-per-kilogram doses, within hours of a defined injury event with a fixed start time — conditions that cannot be replicated by self-injection weeks into a niggling hamstring.

The honest position remains the one we have held across our peptide profiles: no human trial supports TB-500 or thymosin beta-4 for musculoskeletal injury recovery. The strongest completed human work on Tβ4 to date has been ophthalmic (topical eye drops), and this cardiac trial missed its overall endpoint. That is the evidence base, as it stands in September 2026.

Is TB-500 legal in Australia? The regulatory angle

Australia's position is unusually strict, and it predates all of this research.

Thymosin beta-4 and TB-500 sit in Schedule 4 and in Appendix D, Item 5 of the Poisons Standard, following scheduling consideration in 2016. Appendix D, Item 5 covers substances for which possession without authority is an offence — that is, possession outside a valid prescription, not merely supply. The TGA's scheduling rationale explicitly cited use to enhance sporting performance and the need to control how these substances are advertised, sold and accessed.

The sporting context is equally concrete. In January 2016, the Court of Arbitration for Sport upheld anti-doping violations against 34 past and present Essendon players in a case centred on thymosin beta-4. Tβ4 and its fragments remain prohibited at all times under Section S2 of the WADA Prohibited List, and validated LC-MS/MS detection methods for TB-500 have been published since 2012, initially for equine urine and plasma at sub-nanogram-per-millilitre sensitivity.

So: not an approved medicine in Australia for any indication; a prescription-only substance with possession controls attached; and a banned substance in sport with laboratory methods able to find it. A positive readout in a Chinese cardiac trial does not shift any of that.

What to watch next

The useful question is not "does TB-500 work" — it is "does anyone run the trial that would answer it". For thymosin beta-4, the live programs are cardiac (NL005 Phase IIc) and ophthalmic. Nobody is running a randomised soft-tissue injury trial. Until someone does, the injury-recovery case rests on animal models and anecdote.

We track this kind of readout as it happens, without the hype. Join the free updates list for plain-language coverage of peptide research and Australian regulatory changes.

FAQ

What is TB-500 used for?

TB-500 is marketed for soft-tissue injury recovery, but no human trial supports that use. The compound is a synthetic fragment of thymosin beta-4; the full-length protein has been trialled in eye disease and, most recently, in heart attack patients — not in tendon or muscle injury.

Is TB-500 legal in Australia?

No, not for general purchase or possession. Thymosin beta-4 and TB-500 are in Schedule 4 and Appendix D, Item 5 of the Poisons Standard, meaning possession without a valid prescription is an offence. Neither is approved by the TGA for any indication.

Does TB-500 heal injuries faster?

There is no randomised human evidence that it does. The supporting data are animal models and case reports. The 2025 cardiac trial of recombinant thymosin beta-4 missed its overall endpoint, and it studied a different molecule, route and tissue entirely.

Can TB-500 be detected in a drug test?

Yes. Thymosin beta-4 and its fragments are prohibited at all times under Section S2 of the WADA Prohibited List, and LC-MS/MS detection methods for TB-500 have been published and used in doping control since 2012.

Sources

This article is independent information, not medical advice. Thymosin beta-4 and TB-500 are not approved by the TGA or FDA for any indication; both are investigational, prescription-controlled in Australia under Appendix D, and prohibited in sport. Speak to a qualified health professional about any treatment decision.